We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





COVID-19 Test Uses Novel High-Throughput Molecular Method for Detecting SARS-CoV-2 Infection in Saliva Samples

By LabMedica International staff writers
Posted on 30 Mar 2021
A new COVID-19 test uses a high-throughput molecular method for detecting infection by SARS-CoV-2 in specimens of saliva from individuals, allowing for fast and accurate detection of infection by the virus.

Escher Biomedical Diagnostics, LLC’s (Houston, TX, USA) Escher BT-MED COV19 Saliva Test has been accepted by FDA as a Notification under Section IV.C of the Emergency Use Authorization program. More...
The BT-MED COV19 Test system is a high-throughput molecular method for detecting infection by the SARS-CoV-2 virus in specimens of saliva from individuals suspected of COVID-19 by their healthcare provider. Escher intends to distribute the COVID-19 virus test in the US while FDA review of the EUA request is pending. At present, the BT-MED COV19 Test is for use only in CLIA-high-complexity laboratories.

The BT-MED system is composed of the BT-MED Analyzer and test kits associated with specific pathogens or panels of pathogens. The analyzer can be configured for full automated use, which minimizes the need for human technical activities, or partial automated use, which allows higher throughput. The BT-MED diagnostic device is based on in situ hybridization with fluorescent molecular probe, coupled with automated intelligent digital image processing that evaluates as to the presence or absence of the virus. There is no 'RT' and No 'PCR' because the BT-MED COV19 method uses alternate methods to amplify the signal due to the virus.

"We are pleased to introduce this important method to the detection and characterization of pathogens. The novel approach developed by Biotrack BV allows fast and accurate detection of the COVID-19 virus within infected human cells that appear in saliva," said Phil Speros of Escher. "And there are many advantages to saliva as a specimen, such as simplicity of collection, but also the ability to verify correct sample collection simply by observing the presence of the necessary small volume. These are important advantages over swab-based methods."

"After years of development our technology has come of age as a robust device that is simple to deploy and implement, even to challenging settings such as trucks and ships," said Gerard Schouten, CEO of Biotrack BV, the manufacturer of the test system. "Implementation in a clinical laboratory is easy. The fact that our system directly observes the molecular probe-lit viral nucleic acids in the infected human cells [shed in saliva] made it possible to create automated software to determine whether there is an infection or not."

Related Links:
Escher Biomedical Diagnostics, LLC


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
New
Slide Scanner System
NanoZoomer S540MD
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.